Order Article Reprints

Meireson A, Tavernier SJ, Van Gassen S, Sundahl N, Demeyer A, Spaas M, Kruse V, Ferdinande L, Van Dorpe J, Hennart B, et al. Immune Monitoring in Melanoma and Urothelial Cancer Patients Treated with Anti-PD-1 Immunotherapy and SBRT Discloses Tumor Specific Immune Signatures. Cancers. 2021; 13(11):2630. https://doi.org/10.3390/cancers13112630

Meireson, Annabel, Simon J. Tavernier, Sofie Van Gassen, Nora Sundahl, Annelies Demeyer, Mathieu Spaas, Vibeke Kruse, Liesbeth Ferdinande, Jo Van Dorpe, Benjamin Hennart, and et al. 2021. "Immune Monitoring in Melanoma and Urothelial Cancer Patients Treated with Anti-PD-1 Immunotherapy and SBRT Discloses Tumor Specific Immune Signatures" Cancers 13, no. 11: 2630. https://doi.org/10.3390/cancers13112630

Meireson, A., Tavernier, S. J., Van Gassen, S., Sundahl, N., Demeyer, A., Spaas, M., Kruse, V., Ferdinande, L., Van Dorpe, J., Hennart, B., Allorge, D., Haerynck, F., Decaestecker, K., Rottey, S., Saeys, Y., Ost, P., & Brochez, L. (2021). Immune Monitoring in Melanoma and Urothelial Cancer Patients Treated with Anti-PD-1 Immunotherapy and SBRT Discloses Tumor Specific Immune Signatures. Cancers, 13(11), 2630. https://doi.org/10.3390/cancers13112630